OC-0425 Clinical experience with stereotactic MR- guided adaptive radiation therapy for pancreatic tumors

A Bruynzeel; F Lagerwaard; O Bohoudi; S Tetar; N Haasbeek; S S Oei; B Slotman; M Meijerink; S Senan; M. Palacios

doi:https://doi.org/10.1016/s0167-8140(17)30867-8

OC-0425 Clinical experience with stereotactic MR- guided adaptive radiation therapy for pancreatic tumors

A Bruynzeel, F Lagerwaard, O Bohoudi, S Tetar, N Haasbeek, S S Oei, B Slotman, M Meijerink, S Senan, M. Palacios

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose or Objective The duodenum is the primary dose-limiting organ when performing SBRT for locally advanced pancreatic cancer (LAPC). With technical and imaging advancements, the incidence of grade ≥3 small bowel toxicity (bleeding, perforation, strictures) has decreased to

Original language	English
Pages (from-to)	S224-S225
Journal	Radiotherapy and oncology
Volume	123
DOIs	https://doi.org/10.1016/s0167-8140(17)30867-8
Publication status	Published - 2017

Access to Document

https://doi.org/10.1016/s0167-8140(17)30867-8

Cite this

@article{282dbb0a4e4a4a20a73b25c42611438e,

title = "OC-0425 Clinical experience with stereotactic MR- guided adaptive radiation therapy for pancreatic tumors",

abstract = "Purpose or Objective The duodenum is the primary dose-limiting organ when performing SBRT for locally advanced pancreatic cancer (LAPC). With technical and imaging advancements, the incidence of grade ≥3 small bowel toxicity (bleeding, perforation, strictures) has decreased to",

author = "A Bruynzeel and F Lagerwaard and O Bohoudi and S Tetar and N Haasbeek and Oei, {S S} and B Slotman and M Meijerink and S Senan and M. Palacios",

year = "2017",

doi = "https://doi.org/10.1016/s0167-8140(17)30867-8",

language = "English",

volume = "123",

pages = "S224--S225",

journal = "Radiotherapy and oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - OC-0425 Clinical experience with stereotactic MR- guided adaptive radiation therapy for pancreatic tumors

AU - Bruynzeel, A

AU - Lagerwaard, F

AU - Bohoudi, O

AU - Tetar, S

AU - Haasbeek, N

AU - Oei, S S

AU - Slotman, B

AU - Meijerink, M

AU - Senan, S

AU - Palacios, M.

PY - 2017

Y1 - 2017

N2 - Purpose or Objective The duodenum is the primary dose-limiting organ when performing SBRT for locally advanced pancreatic cancer (LAPC). With technical and imaging advancements, the incidence of grade ≥3 small bowel toxicity (bleeding, perforation, strictures) has decreased to

AB - Purpose or Objective The duodenum is the primary dose-limiting organ when performing SBRT for locally advanced pancreatic cancer (LAPC). With technical and imaging advancements, the incidence of grade ≥3 small bowel toxicity (bleeding, perforation, strictures) has decreased to

U2 - https://doi.org/10.1016/s0167-8140(17)30867-8

DO - https://doi.org/10.1016/s0167-8140(17)30867-8

M3 - Article

SN - 0167-8140

VL - 123

SP - S224-S225

JO - Radiotherapy and oncology

JF - Radiotherapy and oncology

ER -